Glytec Advances Market Leadership in Critical Time for the Hospital Industry

Patient outcomes, client growth, and industry cost savings align to new, CMS requirements for hospitals

BOSTON, Feb. 13, 2025 /PRNewswire/ -- Glytec, the pioneer in cloud-based diabetes and insulin management Software-as-a-Service (SaaS) technology completed a record year of nationwide patient and hospital impact, helping the industry establish a more solid clinical and financial foundation as well as prepare for new, CMS reporting requirements related to inpatient diabetes management.

In 2024, Glytec increased its customer base and overall healthcare impact significantly, driven by a combination of over 20 new and expanded client accounts.  Across these new and existing hospitals, Glytec clients in aggregate achieved a 43% reduction in hypoglycemia rates (<70 mg/dL) compared to the industry standard, an 88% reduction in severe hypoglycemia rates (<40 mg/dL), and millions in savings by avoiding treatable hypoglycemia and improving intensive care unit (ICU) throughput alone.

These patient wins and validated industry outcomes come at a critical time for hospitals as they prepare for new CMS reporting requirements.  Beginning in fiscal year 2026, hospitals will be required to report severe hypoglycemia (stays with blood glucose <40 mg/dL) and hyperglycemia (treatable days with blood glucose >300 mg/dL) in addition to the prior list of electronic clinical quality measures (eCQMs) or face a reduction in Medicare reimbursement.

"Glytec worked tirelessly on behalf of our clients and patients in 2024, and we feel a deep sense of accomplishment for the impact we have had on outcomes and economics," said Patrick Cua, CEO of Glytec. "The increasing adoption of Glucommander as the industry standard for inpatient diabetes management positions Glytec for continued success in 2025 and further validates the trust of our clients and patients."

Glytec's industry-leading software addresses timely, critical challenges for the healthcare industry. One-third of all hospitalized patients require insulin therapy to regulate high blood sugar during their stay.¹ More than 2 million patients each year experience an adverse event in the hospital leading to hypoglycemia, costing the healthcare system over 8 billion dollars. Yet nearly one-third of hospitals have no glucose management metrics, and 59% do not have an automated method of pulling data on rates of hyperglycemia and hypoglycemia.²

With over 350 hospital clients and growing, Glytec is committed to addressing the needs of millions of patients and the entire hospital industry in advancing diabetes care, outcomes, and safety.

About Glytec
Glytec's industry-leading SaaS platform, trusted by 350+ hospitals, empowers collaborative diabetes management and insulin dosing—improving patient outcomes, reducing length of stay, and streamlining workflows while delivering a 6-8x ROI. The first-ever FDA-cleared cloud-based insulin management software is EMR-integrated, easy to set up, and validated by over 100 patents and over 100 publications. It's built by a mission-driven team dedicated to helping healthcare leaders, clinicians and patients promote health equity and improve diabetes outcomes from hospital to home.

For more information, follow Glytec on LinkedIn, or visit www.glytec.com.

Sources

1. Umpierrez, et al. J of Clin Endo & Met. 87, no. 3 (March 2002): 978–82. https://doi.org/10.1210/jcem.87.3.8341.
2. Cook, et al. End Pract. 16, no. 2 (March 2010): 219-30. https://doi.org/10.4158/EP09234.OR.

Contact Information
Public Relations
[email protected]

SOURCE Glytec, LLC